Clinical trials: Chronic Pulmonary Obstruction
Chronic Obstructive Pulmonary Disease
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
- Trial name
- NCT00419744
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
This is a randomized, double blind, double dummy, active-controlled, parallel-group study to assess the efficacy and Safety of HRG2005 inhalation in patients with moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT06035393
- Testing
- HRG2005 inhalation, Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238184
- Testing
- Atrovent®, Ventilat®
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this trial is to compare the efficacy and the safety of Ba 679 BR Respimat 5 ug once daily to tiotropium inhalation capsule 18 ug (Spiriva inhalation capsule) in a crossover study of 4-week treatment periods in…
- Trial name
- NCT00292448
- Testing
- Ba 679 BR Respimat, Tiotropium (Spiriva) inhalation capsule 18 ug
- Where
- 27 sites in Japan
- Volunteers
- 157 people
- Sponsor
- Boehringer Ingelheim
Chronic Diseases
Evaluation of the Performance of an e-Health System
Prospective, non-randomized, open-label, pilot study conducted in a single group of 30 evaluable patients, i.e. patients completing an approximate 3 month follow-up.
- Trial name
- NCT02803489
- Testing
- medical device intervention
- Where
- 6 sites in France
- Volunteers
- 23 people
- Sponsor
- Air Liquide Santé International
Chronic Obstructive Pulmonary Disease
AZD9668 Relative Bioavailability
This clinical study will aid future formulation development and optimisation of AZD9668 tablets by evaluating possible effects of minor changes to the formulation and process on the rate and extent of absorption.
- Trial name
- NCT01035411
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to two doses [25 μg (1 capsule) and 50 μg (2 capsules of 25 μg)] salmeterol, administered as the xinafoate salt, in an inhalation…
- Trial name
- NCT02238106
- Testing
- Salmeterol medium dose, Salmeterol low dose, Salmeterol high dose
- Volunteers
- 136 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD
Chronic Obstructive Pulmonary Disease (COPD) is a major health concern, with a substantial impact on a patient's life. However, the impact of COPD is currently under-recognised and, as a result, COPD is under-treated.
- Trial name
- PACE (NCT01254032)
- Where
- 19 sites in Australia, China and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
COPD
Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)
A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion (IV) of Zofin for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT05643729
- Testing
- Zofin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ZEO ScientifiX, Inc.
Healthy, COPD
A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled AZD9164 following administration of multiple ascending doses in healthy male and female subjects and COPD…
- Trial name
- NCT01016951
- Testing
- AZD9164 Turbuhaler®
- Where
- 2 sites in Sweden
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)
- Trial name
- NCT01054170
- Testing
- AZD9668
- Where
- 9 sites in Canada, Denmark and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01867762
- Testing
- JNJ 49095397
- Where
- 47 sites in United States, Belgium and 9 more
- Volunteers
- 211 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
The primary objective of the present study is to evaluate the effect of tiotropium + olodaterol fixed dose combination (FDC) compared to tiotropium monotherapy on the intensity of breathlessness during the 3min constant speed…
- Trial name
- NCT02853123
- Testing
- Tiotropium, Olodaterol
- Where
- 13 sites in Belgium, Canada and 2 more
- Volunteers
- 106 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
The study will evaluate bioavailability, pharmacokinetics, safety, and tolerability of budesonide, glycopyrronium and formoterol (BGF) metered dose inhaler (MDI) formulated with 3 different propellants: Propellant 1 (Treatment A…
- Trial name
- NCT04600505
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants
The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.
- Trial name
- NCT06368440
- Testing
- AZD6793
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COPD
Two-Stage Study to Assess the Efficacy and Safety of 12 Weeks of Treatment With PEP03 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
PEP03 is a new chemical entity developed as a highly selective, potent, and orally active 5-LO inhibitor. PEP03 exerts its action by blocking the generation of both cysteinyl LTs and LTB4.
- Trial name
- NCT00219648
- Testing
- PEP03
- Where
- Taiwan
- Sponsor
- PharmaEngine
Chronic Obstructive Pulmonary Disease
Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity
This study compared the effects of a single dose of indacaterol with that of a single dose of tiotropium on inspiratory capacity.
- Trial name
- NCT00999908
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 11 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001
A phase I randomised, double-blind, placebo-controlled study of single and repeated ascending doses in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of inhaled chf 6001.
- Trial name
- CHF6001Ext (NCT02386761)
- Testing
- Single Ascending Dose (SAD), Multiple Ascending Dose (MAD)
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand
The purpose of this study is to evaluate health status of uncontrolled Chronic Obstructive Pulmonary Disease (COPD) patients in response to treatments in clinical practice.
- Trial name
- NCT01169727
- Where
- 20 sites in Thailand
- Volunteers
- 684 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.
- Trial name
- NCT00984659
- Testing
- Fluticasone propionate/salmeterol combination product, Salmeterol
- Where
- 39 sites in United States
- Volunteers
- 366 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.